Pulsatile Secretion Kinetics and Endocrine Integrity Maintenance Following Intravenous and Subcutaneous Administration of Growth Hormone-Releasing Factor (GRF 1-29) in Human Subjects

Principal Investigators: Vance, M. L., Evans, W. S., Thorner, M. O., et al. (Department of Internal Medicine, University of Virginia School of Medicine)

Methodology: Clinical evaluation of healthy human adult cohorts administered varying doses of synthetic GRF 1-29 via continuous intravenous infusion, intermittent pulses, and subcutaneous injections. Researchers tracked real-time plasma growth hormone concentrations via automated blood sampling at 20-minute intervals over a 24-hour testing block.

Key Findings: Sermorelin administration induced a significant, rapid rise in plasma growth hormone levels. Crucially, even during continuous exposure protocols, Sermorelin did not disrupt the natural pulsatile rhythm of growth hormone release. The pituitary gland continued to pulse in response to natural hypothalamic triggers, demonstrating that Sermorelin preserves native homeostatic feedback controls and avoids the severe hormone-bleeding desensitization common with non-regulated secretagogues.